Diphtheria: all 267 studies

Page 2 of 3. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.

• Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured TdCompletedNCT00601835Phase 4Results posted
• Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058CompletedNCT00548171Phase 4Results posted
• Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™CompletedNCT00534833Phase 3Results posted
• Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino InfantsCompletedNCT00514709Phase 3Results posted
• Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9CompletedNCT00489970Phase 3Results posted
• Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/HibCompletedNCT00473668Phase 3Results posted
• Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of AgeCompletedNCT00467519Phase 3Results posted
• Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same VaccinesCompletedNCT00463437Phase 3Results posted
• A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and OlderCompletedNCT00457249Phase 4Results posted
• Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)CompletedNCT00432042Phase 3Results posted
• Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.CompletedNCT00412854Phase 3Results posted
• Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy InfantsCompletedNCT00404651Phase 3Results posted
• Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai InfantsCompletedNCT00401531Phase 3Results posted
• Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in AdultsCompletedNCT00385255Phase 3Results posted
• Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPVCompletedNCT00362336Phase 3Results posted
• Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®CompletedNCT00355121Phase 2Results posted
• Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy InfantsCompletedNCT00348881Phase 3Results posted
• Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® VaccineCompletedNCT00347958Phase 4Results posted
• Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 YearsCompletedNCT00346073Phase 3Results posted
• Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio VaccineCompletedNCT00343889Phase 3Results posted
• Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)CompletedNCT00337428Phase 3Results posted
• Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy InfantsCompletedNCT00325156Phase 4Results posted
• Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B VaccineCompletedNCT00325143Phase 3Results posted
• Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)CompletedNCT00325130Phase 3Results posted
• Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®CompletedNCT00319553Phase 4Results posted
• Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months ScheduleCompletedNCT00315055Phase 3Results posted
• Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.CompletedNCT00313911Phase 3Results posted
• Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis VaccineCompletedNCT00304265Phase 4Results posted
• Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean InfantsCompletedNCT00303316Phase 3Results posted
• Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy InfantsCompletedNCT00290342Phase 3Results posted
• US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal DiseaseCompletedNCT00282295Phase 4Results posted
• Immunogenicity and Safety of ADACEL™ as Fifth Dose in TaiwanCompletedNCT00258908Phase 3Results posted
• Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®CompletedNCT00258895Phase 3Results posted
• Safety and Immune Response of Different Pediatric Combination Vaccines.CompletedNCT00255047Phase 3Results posted
• Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in ChildrenCompletedNCT00228917Phase 3Results posted
• Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in InfantsCompletedNCT00169442Phase 3Results posted
• Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to InfantsCompletedNCT00158756Phase 3Results posted
• Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV VaccinesCompletedNCT00148941Phase 3Results posted
• Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30mCompletedNCT00136604Phase 3Results posted
• A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant WomenActive, not recruitingNCT07596199Phase 3
• A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 YearsCompletedNCT07596173Phase 3
• Safety Monitoring of Boostagen® Vaccine in ThailandCompletedNCT07444502
• A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary SeriesActive, not recruitingNCT06947499Phase 2/3
• Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined VaccineActive, not recruitingNCT06857370Phase 3
• Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis VaccineCompletedNCT06817187Phase 3
• A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)CompletedNCT06708286Phase 2/3
• Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 MaintenanceActive, not recruitingNCT06070961
• A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)CompletedNCT06056050Phase 1
• A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)Active, not recruitingNCT05951725Phase 3
• Cutaneous Diphtheria in France : Observational, Retrospective Study of Patient CharacteristicsCompletedNCT05798247
• Immunogenicity and Safety of Vaccine Against Tetanus and Diphtheria.Active, not recruitingNCT05480462Phase 3
• Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary SeriesCompletedNCT05457946Phase 2/3
• A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, AdsorbedActive, not recruitingNCT05091619Phase 3
• To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy ChildrenCompletedNCT04618939Phase 3
• To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 YearsStatus unknownNCT04618640Phase 3
• Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in ThailandCompletedNCT04429295Phase 3
• Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36Status unknownNCT04424693Phase 4
• Adapting Motivational Interviewing for Maternal Immunizations (MI4MI)CompletedNCT04302675Not applicable
• Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South AfricaCompletedNCT04300192Phase 4
• A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy AdultsStatus unknownNCT04238975Phase 2
• Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, UgandaCompletedNCT04177485Not applicable
• Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .CompletedNCT04099303Phase 1
• Immune Response followingTdap Vaccine in PregnancyCompletedNCT04082299
• Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy SubjectsCompletedNCT04075175Phase 1
• Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy InfantsStatus unknownNCT04073459Phase 2
• Sero-epidemiological Survey of England in 2019/2020 - COVID-19CompletedNCT04061382
• A Phase IV Study to Assess the Safety of EupentaTM InjStatus unknownNCT04056728Phase 4
• Diphtheria Vaccination in Adolescents With Inflammatory Bowel DiseaseCompletedNCT03998215Not applicable
• A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in CanadaCompletedNCT03958799Phase 1
• Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care SystemCompletedNCT03950986Not applicable
• The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 WeeksCompletedNCT03931239Not applicable
• Evaluation of an Infant Immunization Encouragement Program in NigeriaCompletedNCT03870061Not applicable
• High and Low Resource Interventions to Promote HPV VaccinesCompletedNCT03824093Not applicable
• Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate VaccineCompletedNCT03552445Phase 4
• Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in PakistanStatus unknownNCT03341195Not applicable
• A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy AdultsCompletedNCT03208101Phase 1
• Immunogenicity of a Single Dose of GSK Biologicals' Boostrix™ in Infants Prior to Primary Pertussis Vaccination, When Administered to Pregnant Women as Per Routine Practice in Bogota, ColombiaTerminatedNCT03188458Phase 4
• Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian InfantsWithdrawnNCT03128489Phase 3
• DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected InfantsCompletedNCT02817451Phase 3
• Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) VaccineStatus unknownNCT02813486Phase 1/2
• Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.CompletedNCT02569879
• Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruSCompletedNCT02458183Phase 3
• Duration of Protection: GSK DTaP VaccinesCompletedNCT02447978
• Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After BirthCompletedNCT02428491Phase 3
• DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese InfantsCompletedNCT02274285Phase 3
• Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 WeeksStatus unknownNCT02257645
• DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed InfantsCompletedNCT02094833Phase 3
• A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' AssaysCompletedNCT02072525Phase 4
• Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated PoliomyelitisCompletedNCT02040636Phase 2
• Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.CompletedNCT01993173Phase 3
• Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa VaccinationCompletedNCT01983540Phase 3
• A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and UnijectCompletedNCT01917357Phase 3
• Hepatitis B Vaccination in InfantsCompletedNCT01896596Phase 4
• Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among InfantsCompletedNCT01890850
• Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western KenyaCompletedNCT01878435Not applicable
• Post Authorisation Safety Study of Triaxis as a 5th Dose in 4-6 Year Old Spanish ChildrenCompletedNCT01583049
• Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in KoreaCompletedNCT01568060
• Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRECompletedNCT01546909Phase 4
• Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in ChinaCompletedNCT01491087Phase 4
• Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of AgeCompletedNCT01470287Phase 3

← Diphtheria overview